MIRUM PHARMAC. DL-0001
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille … Read more
MIRUM PHARMAC. DL-0001 (08D) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, MIRUM PHARMAC. DL-0001 (08D) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MIRUM PHARMAC. DL-0001 - Net Assets Trend (None–None)
This chart illustrates how MIRUM PHARMAC. DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MIRUM PHARMAC. DL-0001 (None–None)
The table below shows the annual net assets of MIRUM PHARMAC. DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to MIRUM PHARMAC. DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
MIRUM PHARMAC. DL-0001 Competitors by Market Cap
The table below lists competitors of MIRUM PHARMAC. DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
$3.69 Billion |
|
Wan Hai Lines Ltd
TW:2615
|
$3.69 Billion |
|
Swissquote Group Holding Ltd
PINK:SWQGF
|
$3.69 Billion |
|
Sodexo SA
PA:SW
|
$3.69 Billion |
|
Great-West Lifeco Inc 4.50% Non-Cum 1st Pfd Shs Ser I
PINK:GRWTF
|
$3.69 Billion |
|
Globalstar Inc
NYSE MKT:GSAT
|
$3.69 Billion |
|
Lifco AB (publ)
PINK:LFCBY
|
$3.69 Billion |
|
easyJet plc
OTCQX:EJTTF
|
$3.69 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MIRUM PHARMAC. DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares MIRUM PHARMAC. DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently MIRUM PHARMAC. DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares MIRUM PHARMAC. DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MIRUM PHARMAC. DL-0001 (08D) | €- | N/A | N/A | $3.69 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |